LONDON — The Danish firm Genmab said Wednesday it would acquire ProfoundBio for $1.8 billion in cash, the latest in a string of 10-figure deals tied to the booming field of targeted chemotherapies.
The purchase will give Genmab ProfoundBio’s three drug candidates in trials, including one called Rina-S that is in a Phase 2 study for ovarian cancer, as well as preclinical programs. Rina-S is also being explored as a therapy in other solid tumors.
ProfoundBio is a privately held, Seattle-based biotech. It had most recently announced a $112 million Series B round in February.
Click this link for the original source of this article.
Author: Andrew Joseph
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.